3PC-020 Dose-banding of nivolumab

BACKGROUND: Nivolumab is a human monoclonal antibody used in the pneumology unit to treat patients with metastatic non-small cell lung cancer (NSCLC) with progression on, or after, platinum-based chemotherapy. Nivolumab is administered intravenously at a dose of 3 mg/kg every 2 weeks or at a dose of...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Eur J Hosp Pharm
Asıl Yazarlar: Frapsauce, A, Laugueux, A, Lester, MA
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMJ Group 2018
Konular:
Section 3: Production and compounding
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535825/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.72
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller